MTOR and nonpapillary renal cell carcinoma: These findings exhibit that ALDH9A1 can be regarded as a reliable prognostic marker and deliver comprehensive insights into the regulations and functions of the AKT-mTOR pathway in ccRCC, thereby establishing a solid research foundation of new therapeutic approaches for ccRCC patients (Fig. 9).